Novo Nordisk A/S (NVO)
| Market Cap | 393.39B |
| Revenue (ttm) | 40.47B |
| Net Income (ttm) | 14.17B |
| Shares Out | 4.45B |
| EPS (ttm) | 3.17 |
| PE Ratio | 27.77 |
| Forward PE | 24.01 |
| Dividend | $1.44 (1.67%) |
| Ex-Dividend Date | Aug 16, 2024 |
| Volume | 1,985,137 |
| Open | 86.97 |
| Previous Close | 87.37 |
| Day's Range | 85.76 - 87.01 |
| 52-Week Range | 81.50 - 148.15 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 134.00 (+55.08%) |
| Earnings Date | Feb 5, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $134.0, which is an increase of 55.08% from the latest price.
News
Novo Nordisk is 'losing its pep' in GLP-1 race: BMO analyst
Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets c...
CagriSema still keeps the Novo Nordisk story in tact, says Barclays' Emily Field
Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental Cagri...
Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk's recent CagriSema study disappointed and led to a massive selloff as investor pessimism deepened. Eli Lilly stock's relative outperformance could strengthen its bullish case, but NVO isn...
Retail investors buy Novo dip after disappointing weight-loss drug data
U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda R...
Will Novo Nordisk (NVO) Stock Recover To $145 Levels?
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of this year. In contrast, its closest peer, Eli Lilly stock is down 15% over ...
The Big 3: CAT, NVO, VZ
Caterpillar (CAT) has given back all of its post-election rally, and Kenny Polcari says the stock could hover around current levels before retesting $412 in the new year. Kenny's also looking at poten...
Novo Nordisk shares rebound 8%: can European markets sustain the rally?
Novo Nordisk shares staged a dramatic rebound on Monday, recovering 8% after a steep 20% plunge on Friday. The recovery was sparked by investor reassessment of the company's potential following disapp...
Eli Lilly, Novo Nordisk Stocks Rise After One Just Hit a Landmark
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.
Novo Nordisk's 27% drop was market overreaction, analysts say
Trials of semaglutide in patients with Alzheimer's and CagriSema in obese patients diabetes could give investors reason to be optimistic, Intron Health's analysts said
European Energy A/S: European Energy and Novo Holdings completes transaction regarding Joint Venture of 17 wind farms in Germany
European Energy A/S: European Energy and Novo Holdings completes transaction regarding Joint Venture of 17 wind farms in Germany Company Announcement 21/2024 (23.12.2024) Today, European Energy A/S ha...
US FDA approves Novo Nordisk's bleeding disorder drug
The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes in patients with a type of blood-related disorder called hemophilia A, the a...
BMO's Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints
Evan David Seigerman, BMO managing director, joins 'Fast Money' to discuss Novo sinking on its obesity drug data.
Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging
Emily Field, Barclays head of European pharmaceutical research, joins CNBC's 'The Exchange' to discuss why Novo Nordisk shares are falling, the competition in the weight-loss drug space, and more.
Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture
The CNBC 'Halftime Report' Investment Committee discusses today's market movers.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms
CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant tumblin...
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 300 points on Friday.
Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss
Novo Nordisk A/S NVO is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data.
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highes...
Novo Nordisk stock just tanked 25%: here's what happened
Novo Nordisk A/S (CPH: NOVO-B) is being punished this morning after posting a disappointing update related to CagriSema. The pharmaceutical behemoth said its experimental weight-loss treatment helped ...
Novo Nordisk shares plummet after weight-loss drug's disappointing trial results
Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.
Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says
Emily Field, Barclays' head of European pharmaceutical research, reacts to the selloff in Novo Nordisk's shares after its experimental obesity shot CagriSema failed to meet expectations. She speaks on...
Novo Nordisk stock plunges on obesity shot trial results
Novo Nordisk (NVO) is falling by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted in i...
Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial
Shares of Novo Nordisk A/S are down after underwhelming REDEFINE-1 trial results. The results were positive, but underperformed company and market expectations (including my own). The trial's flexible...
PCE Data Lower Than Expected, NVO Falls on New Obesity Drug, AFRM Upgraded
Jenny Horne joins the Futures show with live reaction to the latest PCE inflation data. November rate rose just 0.1% from October, but on an annual basis checked in at 2.4% On the stock front, Novo No...
Novo Nordisk Stock: A Rare Buying Opportunity
As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a r...